Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BioCryst Pharmaceuticals Inc
BCRX | US
8.58
USD-0.61
-6.64%
BCRX | US
About BioCryst Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/04/2026
Close
8.58
Open
9.20
High
9.27
Low
8.56
BioCryst Pharmaceuticals Inc. a biotechnology company discovers novel oral and small-molecule medicines. The company markets peramivir injection an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB RAPIACTA and PERAMIFLU names; and ORLADEYO an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930 an oral factor D inhibitor for complement-mediated diseases; and Galidesivir to treat various RNA viruses including Marburg Yellow Fever Ebola and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co. Ltd.; Seqirus UK Limited; Shionogi & Co. Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research Ltd. BioCryst Pharmaceuticals Inc. was founded in 1986 and is headquartered in Durham North Carolina.
View LessBCRX | US
Risk
42.9
Sharpe
0.22
Luna's Score
45/100
Recommendation
Sell
Luna says (BCRX | US)
What's Working
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
45.2%1 month
42.9%3 months
50.8%6 months
48.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
56.59
Debt to equity
-1.79
Debt to assets
1.80
Ent. to EBITDA
-12.20
Ent. to rev.
5.49
PEG
-0.28
Other Fundamentals
EBITDA
-52.71M
MarketCap
1.78B
MarketCap(USD)
1.78B
Div. yield
-
Op. margin
8.01
Erngs. growth
-
Rev. growth
32.50
Ret. on equity
-1.93K
Short ratio
12.78
Short perc.
11.32
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.42
Range1M
1.57
Range3M
4.09
Volumes: Market Activity
Rel. volume
0.95
Price X volume
42.34M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -12.20 | - | Cheaper |
| Ent. to Revenue | 5.49 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 56.59 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 50.81 | - | Lower Risk |
| Debt to Equity | -1.79 | -1.23 | Cheaper |
| Debt to Assets | 1.80 | 0.25 | Expensive |
| Market Cap | 1.78B | - | Emerging |
